Trial NCT04891133; EudraCT 2021-000541-41; EU CTIS 2022-500385-99-00
Publication Bari-SolidAct - Troseid M, SSRN (2022) (preprint)
Dates: 2021-06-03 to 2022-03-07
Funding: Mixed (European Commission; EU-SolidAct is part of the European pandemic preparedness network EU RESPONSE, funded by the EU Horizon 2020 Research and Innovation Programme. EU-SolidAct has also received funding from CAPNET (France) and Klinbeforsk (Norway). The baricitinib drug and matching placebo were provided by Eli Lilly and Company. )
Conflict of interest: Yes